Chengda Pharmaceuticals (301201.SZ) faces a reduction of 860,000 shares by its major shareholder, Qianhai Shengtai.

12/03/2025

GMT Eight

Chengda Pharmaceuticals (301201.SZ) announced that its shareholder, Qianhai Shengtai, holding more than 5% of the shares, will reduce its holding of 860,000 shares of the company through block trading from March 6, 2025 to March 11, 2025, representing 0.57% of the total share capital of the company after excluding the shares held in the repurchase account.

Northbound funds | Northbound trading net purchased 26.212 billion yuan, Northbound trading once again increased its positions in the Hong Kong Stock ETF, with a total of over 8.2 billion Hong Kong dollars sought throughout the day for the TRACKER FUND OF HONG KONG (02800).

SWIRE PROPERTIES (01972) spent 9.6282 million Hong Kong dollars to repurchase 600,000 shares on March 12th.

Contact: contact@gmteight.com

Chengda Pharmaceuticals (301201.SZ) faces a reduction of 860,000 shares by its major shareholder, Qianhai Shengtai.

RECOMMEND

SHANSHUI CEMENT (00691) announced its performance for 2024, with a net loss attributable to owners of approximately 141 million yuan, narrowed by 84.09% year-on-year.

A femtosecond laser corneal refractive surgery system and related consumables produced by an important upstream partner represented by GAUSH MEDITECH (02407) have obtained the Medical Device Registration Certificate from the National Medical Products Administration.

LEON INSPECTION (01586): Achieving breakthroughs in innovative application technologies and officially deploying them in three major application scenarios.